Suppr超能文献

新型 BMP7 和 HGF 基因治疗诱导选择性肌成纤维细胞凋亡并减少体内角膜混浊。

Novel Combination BMP7 and HGF Gene Therapy Instigates Selective Myofibroblast Apoptosis and Reduces Corneal Haze In Vivo.

机构信息

Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri, United States.

One-Health One-Medicine Ophthalmology and Vision Research Center, University of Missouri Columbia, Missouri, United States.

出版信息

Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):1045-1057. doi: 10.1167/iovs.17-23308.

Abstract

PURPOSE

We tested the potential of bone morphogenic protein 7 (BMP7) and hepatocyte growth factor (HGF) combination gene therapy to treat preformed corneal fibrosis using established rabbit in vivo and human in vitro models.

METHODS

Eighteen New Zealand White rabbits were used. Corneal fibrosis was produced by alkali injury. Twenty-four hours after scar formation, cornea received topically either balanced salt solution (BSS; n = 6), polyethylenimine-conjugated gold nanoparticle (PEI2-GNP)-naked plasmid (n = 6) or PEI2-GNP plasmids expressing BMP7 and HGF genes (n = 6). Donor human corneas were used to obtain primary human corneal fibroblasts and myofibroblasts for mechanistic studies. Gene therapy effects on corneal fibrosis and ocular safety were evaluated by slit-lamp microscope, stereo microscopes, quantitative real-time PCR, immunofluorescence, TUNEL, modified MacDonald-Shadduck scoring system, and Draize tests.

RESULTS

PEI2-GNP-mediated BMP7+HGF gene therapy significantly decreased corneal fibrosis in live rabbits in vivo (Fantes scale was 0.6 in BMP7+HGF-treated eyes compared to 3.3 in -therapy group; P < 0.001). Corneas that received BMP7+HGF demonstrated significantly reduced mRNA levels of profibrotic genes: α-SMA (3.2-fold; P < 0.01), fibronectin (2.3-fold, P < 0.01), collagen I (2.1-fold, P < 0.01), collagen III (1.6-fold, P < 0.01), and collagen IV (1.9-fold, P < 0.01) compared to the -therapy corneas. Furthermore, BMP7+HGF-treated corneas showed significantly fewer myofibroblasts compared to the -therapy controls (83%; P < 0.001). The PEI2-GNP introduced >104 gene copies per microgram DNA of BMP7 and HGF genes. The recombinant HGF rendered apoptosis in corneal myofibroblasts but not in fibroblasts. Localized topical BMP7+HGF therapy showed no ocular toxicity.

CONCLUSIONS

Localized topical BMP7+HGF gene therapy treats corneal fibrosis and restores transparency in vivo mitigating excessive healing and rendering selective apoptosis in myofibroblasts.

摘要

目的

我们通过建立兔体内和人体外模型,检测骨形态发生蛋白 7(BMP7)和肝细胞生长因子(HGF)联合基因治疗治疗已形成的角膜纤维化的潜力。

方法

18 只新西兰白兔用于研究。通过碱烧伤诱导角膜纤维化。瘢痕形成 24 小时后,角膜表面分别给予平衡盐溶液(BSS;n=6)、聚乙烯亚胺-金纳米颗粒(PEI2-GNP)-裸质粒(n=6)或表达 BMP7 和 HGF 基因的 PEI2-GNP 质粒(n=6)。使用供体人角膜获得原代人角膜成纤维细胞和肌成纤维细胞,进行机制研究。通过裂隙灯显微镜、体视显微镜、实时定量 PCR、免疫荧光、TUNEL、改良麦克唐纳-沙杜克评分系统和德莱兹试验评估基因治疗对角膜纤维化和眼部安全性的影响。

结果

PEI2-GNP 介导的 BMP7+HGF 基因治疗显著降低了活体兔体内的角膜纤维化(Fantes 评分治疗组为 0.6,对照组为 3.3;P<0.001)。接受 BMP7+HGF 治疗的角膜显示出显著降低的促纤维化基因 mRNA 水平:α-SMA(3.2 倍;P<0.01)、纤维连接蛋白(2.3 倍,P<0.01)、I 型胶原(2.1 倍,P<0.01)、III 型胶原(1.6 倍,P<0.01)和 IV 型胶原(1.9 倍,P<0.01)与对照组相比。此外,与对照组相比,BMP7+HGF 治疗的角膜中的肌成纤维细胞明显减少(83%;P<0.001)。PEI2-GNP 转导的 BMP7 和 HGF 基因的每个微克 DNA 超过 104 个基因拷贝。重组 HGF 使角膜肌成纤维细胞发生凋亡,但不使成纤维细胞发生凋亡。局部表面 BMP7+HGF 治疗无眼部毒性。

结论

局部表面 BMP7+HGF 基因治疗可治疗角膜纤维化并恢复体内透明度,减轻过度愈合,并使肌成纤维细胞选择性凋亡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b0b/5822743/8192e1a5d71c/i1552-5783-59-2-1045-f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验